{"organizations": [], "uuid": "9adea28443384029b4912f39cf97d0cea9bde47e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alexion-reports-q1-results-and-pos/brief-alexion-reports-q1-results-and-positive-topline-data-from-alxn1210-phase-3-pnh-switch-study-idUSASC09XM7", "country": "US", "domain_rank": 408, "title": "Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T18:36:00.000+03:00", "replies_count": 0, "uuid": "9adea28443384029b4912f39cf97d0cea9bde47e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alexion-reports-q1-results-and-pos/brief-alexion-reports-q1-results-and-positive-topline-data-from-alxn1210-phase-3-pnh-switch-study-idUSASC09XM7", "ord_in_thread": 0, "title": "Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alexion", "sentiment": "negative"}, {"name": "alexion pharmaceuticals inc", "sentiment": "negative"}, {"name": "pnh", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "alexion pharmaceuticals", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Alexion Pharmaceuticals Inc:\n* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY\n* Q1 NON-GAAP EARNINGS PER SHARE $1.68\n* Q1 GAAP EARNINGS PER SHARE $1.11 * Q1 REVENUE $930.9 MILLION VERSUS I/B/E/S VIEW $923.5 MILLION\n* Q1 EARNINGS PER SHARE VIEW $1.50 — THOMSON REUTERS I/B/E/S\n* REGULATORY SUBMISSIONS FROM ALXN1210 PHASE 3 PNH NAIVE AND SWITCH STUDIES PLANNED IN U.S. AND EU IN MID-2018\n* ALEXION PHARMACEUTICALS - ALXN1210 WAS GENERALLY WELL TOLERATED IN PHASE 3 SWITCH STUDY WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT FOR SOLIRIS\n* ALEXION - PHASE 3 SWITCH STUDY SHOWED NON-INFERIORITY OF ALXN1210 TO SOLIRIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAD BEEN STABLE ON SOLIRIS\n* PHASE 3 SWITCH STUDY ALSO DEMONSTRATED NON-INFERIORITY ON ALL FOUR KEY SECONDARY ENDPOINTS\n* SEES 2018 TOTAL REVENUES $3,925 TO $3,985 MILLION * SEES 2018 SOLIRIS REVENUES OF $3,380 MILLION TO $3,420 MILLION\n* SEES 2018 EARNINGS PER SHARE $1.35 TO $1.75 * SEES 2018 NON-GAAP EARNINGS PER SHARE $6.75 TO $6.90\n* FY2018 EARNINGS PER SHARE VIEW $6.86, REVENUE VIEW $3.98 BILLION — THOMSON REUTERS I/B/E/S\n* ALEXION - 2018 FINANCIAL GUIDANCE ASSUMES UNFAVORABLE SOLIRIS REVENUE IMPACT OF $90-$110 MILLION FROM ALXN1210 & OTHER CLINICAL TRIAL RECRUITMENT VERSUS PRIOR YEAR\n* EXPECTS TO INCUR ADDITIONAL RESTRUCTURING AND RELATED EXPENSES OF APPROXIMATELY $15 MILLION TO $80 MILLION IN 2018 Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T18:36:00.000+03:00", "crawled": "2018-04-27T16:42:38.014+03:00", "highlightTitle": ""}